--- title: "Eloralintide (LY3841136): Dosing & Vendor Prices" description: "Eloralintide (LY3841136): dosing protocols, mechanism & side effects. Compare 1 verified vendor prices." lang: en json-ld: | [ { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Compounds", "item": "https://www.bodyhackguide.co/compare" }, { "@type": "ListItem", "position": 3, "name": "Eloralintide (LY3841136)" } ] }, { "@context": "https://schema.org", "@type": "Product", "name": "Eloralintide (LY3841136)", "description": "Eloralintide is an amylin analog developed by Eli Lilly and Company for weight management, given as a once-weekly subcutaneous injection. It is a 37 amino acid peptide containing three non-coded residues and a C20 fatty diacid that binds albumin, which is what stretches its action out to a week (PMID: 41109426). It is investigational everywhere. No regulator has approved it, and it is in phase 3 trials as of 2026. Amylin is a hormone released from pancreatic beta cells alongside insulin. It slows gastric emptying, suppresses glucagon after meals and signals meal termination through the brainstem. Pramlintide, the first approved amylin analog, proved the concept but was limited by frequent dosing and modest effect. The newer analogs split into two groups: dual amylin and calcitonin receptor agonists such as cagrilintide, and selective amylin receptor agonists. Eloralintide belongs to the second group. In cells expressing human receptors it activated the amylin 1 receptor about 12-fold more potently than the calcitonin receptor and about 11-fold more potently than the amylin 3 receptor (PMID: 41109426). That selectivity is the design idea, because calcitonin receptor engagement is thought to contribute to nausea. Preclinical results back this up. In lean rats, eloralintide produced significantly less conditioned taste avoidance than cagrilintide, a marker of aversive signaling. In diet-induced obese rats it reduced food intake and lowered body weight in a dose-dependent way, mostly through loss of fat mass, and pharmacokinetics in rats and monkeys supported weekly dosing (PMID: 41109426). The human data are what make this compound notable. A phase 1 single-ascending-dose study in 48 healthy participants reported mostly mild adverse events and week 4 weight reduction of 2.5 percent and 4.4 percent in the two highest single-dose groups against a 0.6 percent gain on placebo (NCT05295940, PMID: 41109426). A 12-week multiple-ascending-dose study in 100 participants with obesity or overweight, run without dose escalation, reported weight reduction across dose groups ranging from 2.6 percent to 11.3 percent, with decreased appetite in 19 percent, headache in 12 percent and fatigue in 11 percent, and infrequent gastrointestinal events: diarrhea in 10 percent, nausea in 8 percent and vomiting in 4 percent (PMID: 41559929). A 48-week phase 2 trial randomized 263 adults across six dose or dose-escalation arms and placebo and reported mean weight change from baseline of about 9 percent to 20 percent against 0.4 percent on placebo, with nausea and fatigue the most common adverse events (NCT06230523, PMID: 41207310). A network meta-analysis of six trials in 4642 adults ranked high-dose eloralintide second only to amycretin for percent body weight reduction, ahead of semaglutide, while noting that gastrointestinal adverse events rose with high doses of amylin-based therapies and that the evidence is still sparse and low certainty (PMID: 42175595). Anything sold outside a trial is not the studied product and has no verified identity or purity.", "url": "https://www.bodyhackguide.co/compound/eloralintide", "image": "https://www.bodyhackguide.co/og-image.png", "brand": { "@type": "Brand", "name": "Research Compound" }, "offers": { "@type": "AggregateOffer", "lowPrice": "179.99", "highPrice": "179.99", "priceCurrency": "USD", "offerCount": "1", "availability": "https://schema.org/InStock", "offers": [ { "@type": "Offer", "price": "179.99", "priceCurrency": "USD", "availability": "https://schema.org/InStock", "itemCondition": "https://schema.org/NewCondition", "url": "https://disguisedalpha.com/product/eloralintide/?coupon=reddit", "seller": { "@type": "Organization", "name": "Disguised Alpha", "url": "https://disguisedalpha.com/?coupon=reddit" }, "name": "Eloralintide (LY3841136) 10mg vial" } ] } }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Eloralintide (LY3841136)", "description": "Eloralintide is an amylin analog developed by Eli Lilly and Company for weight management, given as a once-weekly subcutaneous injection. It is a 37 amino acid peptide containing three non-coded residues and a C20 fatty diacid that binds albumin, which is what stretches its action out to a week (PMID: 41109426). It is investigational everywhere. No regulator has approved it, and it is in phase 3 trials as of 2026. Amylin is a hormone released from pancreatic beta cells alongside insulin. It slows gastric emptying, suppresses glucagon after meals and signals meal termination through the brainstem. Pramlintide, the first approved amylin analog, proved the concept but was limited by frequent dosing and modest effect. The newer analogs split into two groups: dual amylin and calcitonin receptor agonists such as cagrilintide, and selective amylin receptor agonists. Eloralintide belongs to the second group. In cells expressing human receptors it activated the amylin 1 receptor about 12-fold more potently than the calcitonin receptor and about 11-fold more potently than the amylin 3 receptor (PMID: 41109426). That selectivity is the design idea, because calcitonin receptor engagement is thought to contribute to nausea. Preclinical results back this up. In lean rats, eloralintide produced significantly less conditioned taste avoidance than cagrilintide, a marker of aversive signaling. In diet-induced obese rats it reduced food intake and lowered body weight in a dose-dependent way, mostly through loss of fat mass, and pharmacokinetics in rats and monkeys supported weekly dosing (PMID: 41109426). The human data are what make this compound notable. A phase 1 single-ascending-dose study in 48 healthy participants reported mostly mild adverse events and week 4 weight reduction of 2.5 percent and 4.4 percent in the two highest single-dose groups against a 0.6 percent gain on placebo (NCT05295940, PMID: 41109426). A 12-week multiple-ascending-dose study in 100 participants with obesity or overweight, run without dose escalation, reported weight reduction across dose groups ranging from 2.6 percent to 11.3 percent, with decreased appetite in 19 percent, headache in 12 percent and fatigue in 11 percent, and infrequent gastrointestinal events: diarrhea in 10 percent, nausea in 8 percent and vomiting in 4 percent (PMID: 41559929). A 48-week phase 2 trial randomized 263 adults across six dose or dose-escalation arms and placebo and reported mean weight change from baseline of about 9 percent to 20 percent against 0.4 percent on placebo, with nausea and fatigue the most common adverse events (NCT06230523, PMID: 41207310). A network meta-analysis of six trials in 4642 adults ranked high-dose eloralintide second only to amycretin for percent body weight reduction, ahead of semaglutide, while noting that gastrointestinal adverse events rose with high doses of amylin-based therapies and that the evidence is still sparse and low certainty (PMID: 42175595). Anything sold outside a trial is not the studied product and has no verified identity or purity.", "lastReviewed": "2026-09-07T04:46:52.801Z", "url": "https://www.bodyhackguide.co/compound/eloralintide", "author": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "reviewedBy": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" }, "mainContentOfPage": { "@type": "WebPageElement", "cssSelector": "main" }, "about": { "@type": "Drug", "name": "Eloralintide (LY3841136)", "alternateName": [ "LY3841136", "LY-3841136", "AT53786", "Eloralintida" ], "description": "Eloralintide is an amylin analog developed by Eli Lilly and Company for weight management, given as a once-weekly subcutaneous injection. It is a 37 amino acid peptide containing three non-coded residues and a C20 fatty diacid that binds albumin, which is what stretches its action out to a week (PMID: 41109426). It is investigational everywhere. No regulator has approved it, and it is in phase 3 trials as of 2026. Amylin is a hormone released from pancreatic beta cells alongside insulin. It slows gastric emptying, suppresses glucagon after meals and signals meal termination through the brainstem. Pramlintide, the first approved amylin analog, proved the concept but was limited by frequent dosing and modest effect. The newer analogs split into two groups: dual amylin and calcitonin receptor agonists such as cagrilintide, and selective amylin receptor agonists. Eloralintide belongs to the second group. In cells expressing human receptors it activated the amylin 1 receptor about 12-fold more potently than the calcitonin receptor and about 11-fold more potently than the amylin 3 receptor (PMID: 41109426). That selectivity is the design idea, because calcitonin receptor engagement is thought to contribute to nausea. Preclinical results back this up. In lean rats, eloralintide produced significantly less conditioned taste avoidance than cagrilintide, a marker of aversive signaling. In diet-induced obese rats it reduced food intake and lowered body weight in a dose-dependent way, mostly through loss of fat mass, and pharmacokinetics in rats and monkeys supported weekly dosing (PMID: 41109426). The human data are what make this compound notable. A phase 1 single-ascending-dose study in 48 healthy participants reported mostly mild adverse events and week 4 weight reduction of 2.5 percent and 4.4 percent in the two highest single-dose groups against a 0.6 percent gain on placebo (NCT05295940, PMID: 41109426). A 12-week multiple-ascending-dose study in 100 participants with obesity or overweight, run without dose escalation, reported weight reduction across dose groups ranging from 2.6 percent to 11.3 percent, with decreased appetite in 19 percent, headache in 12 percent and fatigue in 11 percent, and infrequent gastrointestinal events: diarrhea in 10 percent, nausea in 8 percent and vomiting in 4 percent (PMID: 41559929). A 48-week phase 2 trial randomized 263 adults across six dose or dose-escalation arms and placebo and reported mean weight change from baseline of about 9 percent to 20 percent against 0.4 percent on placebo, with nausea and fatigue the most common adverse events (NCT06230523, PMID: 41207310). A network meta-analysis of six trials in 4642 adults ranked high-dose eloralintide second only to amycretin for percent body weight reduction, ahead of semaglutide, while noting that gastrointestinal adverse events rose with high doses of amylin-based therapies and that the evidence is still sparse and low certainty (PMID: 42175595). Anything sold outside a trial is not the studied product and has no verified identity or purity.", "activeIngredient": "Eloralintide (LY3841136)", "administrationRoute": "Subcutaneous injection", "mechanismOfAction": "Eloralintide is a selective agonist at the amylin 1 receptor, a complex formed by the calcitonin receptor with receptor activity-modifying protein 1. Activating that receptor in the area postrema and related hindbrain circuits promotes satiation, slows gastric emptying and suppresses postprandial glucagon, the same physiology as endogenous amylin. In cells expressing human receptors, eloralintide activated the amylin 1 receptor about 12-fold more potently than the calcitonin receptor and about 11-fold more potently than the amylin 3 receptor; in rat cells both amylin receptors were activated more potently than the calcitonin receptor (PMID: 41109426). The peptide is a single fatty-acid acylated amylin analog whose C20 fatty diacid drives albumin binding and once-weekly kinetics (PMID: 41109426).", "dosageForm": "vial", "legalStatus": "Not approved for human use — research chemical", "warning": "For research purposes only. Not for human consumption." } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What is Eloralintide (LY3841136) used for in research?", "acceptedAnswer": { "@type": "Answer", "text": "Eloralintide is an amylin analog developed by Eli Lilly and Company for weight management, given as a once-weekly subcutaneous injection. It is a 37 amino acid peptide containing three non-coded residues and a C20 fatty diacid that binds albumin, which is what stretches its action out to a week (PMID: 41109426). It is investigational everywhere. No regulator has approved it, and it is in phase 3 trials as of 2026. Amylin is a hormone released from pancreatic beta cells alongside insulin. It slows gastric emptying, suppresses glucagon after meals and signals meal termination through the brainstem. Pramlintide, the first approved amylin analog, proved the concept but was limited by frequent dosing and modest effect. The newer analogs split into two groups: dual amylin and calcitonin receptor agonists such as cagrilintide, and selective amylin receptor agonists. Eloralintide belongs to the second group. In cells expressing human receptors it activated the amylin 1 receptor about 12-fold more potently than the calcitonin receptor and about 11-fold more potently than the amylin 3 receptor (PMID: 41109426). That selectivity is the design idea, because calcitonin receptor engagement is thought to contribute to nausea. Preclinical results back this up. In lean rats, eloralintide produced significantly less conditioned taste avoidance than cagrilintide, a marker of aversive signaling. In diet-induced obese rats it reduced food intake and lowered body weight in a dose-dependent way, mostly through loss of fat mass, and pharmacokinetics in rats and monkeys supported weekly dosing (PMID: 41109426). The human data are what make this compound notable. A phase 1 single-ascending-dose study in 48 healthy participants reported mostly mild adverse events and week 4 weight reduction of 2.5 percent and 4.4 percent in the two highest single-dose groups against a 0.6 percent gain on placebo (NCT05295940, PMID: 41109426). A 12-week multiple-ascending-dose study in 100 participants with obesity or overweight, run without dose escalation, reported weight reduction across dose groups ranging from 2.6 percent to 11.3 percent, with decreased appetite in 19 percent, headache in 12 percent and fatigue in 11 percent, and infrequent gastrointestinal events: diarrhea in 10 percent, nausea in 8 percent and vomiting in 4 percent (PMID: 41559929). A 48-week phase 2 trial randomized 263 adults across six dose or dose-escalation arms and placebo and reported mean weight change from baseline of about 9 percent to 20 percent against 0.4 percent on placebo, with nausea and fatigue the most common adverse events (NCT06230523, PMID: 41207310). A network meta-analysis of six trials in 4642 adults ranked high-dose eloralintide second only to amycretin for percent body weight reduction, ahead of semaglutide, while noting that gastrointestinal adverse events rose with high doses of amylin-based therapies and that the evidence is still sparse and low certainty (PMID: 42175595). Anything sold outside a trial is not the studied product and has no verified identity or purity." } }, { "@type": "Question", "name": "What forms does Eloralintide (LY3841136) come in?", "acceptedAnswer": { "@type": "Answer", "text": "Eloralintide (LY3841136) is available in vial form." } }, { "@type": "Question", "name": "How much does Eloralintide (LY3841136) cost?", "acceptedAnswer": { "@type": "Answer", "text": "Prices start at $179.99 across 1 verified vendor." } }, { "@type": "Question", "name": "How do I compare Eloralintide (LY3841136) vendors?", "acceptedAnswer": { "@type": "Answer", "text": "Compare prices, payment methods, shipping, and COA scores across 1 vendor." } } ] }, { "@context": "https://schema.org", "@type": "Organization", "@id": "https://www.bodyhackguide.co#organization", "name": "BodyHackGuide", "alternateName": "BHG", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/logo.png", "width": 512, "height": 512 }, "description": "Evidence-based research reference for peptides and nootropics. 124+ compound profiles, interactive dosing calculators, real-time vendor pricing, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. BodyHackGuide and BHG Labs share common ownership, and we earn a commission on purchases through our links.", "foundingDate": "2024", "founder": { "@id": "https://www.bodyhackguide.co/about#person" }, "sameAs": [ "https://x.com/bodyhackguide", "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher", "https://discord.gg/Mhq5UdRYBA" ], "knowsAbout": [ "Peptide research", "Nootropic research", "Biohacking", "Compound dosing", "Vendor transparency" ], "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards", "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards", "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards" } ] --- [Skip to content](#main-content) ## Research Use Only This site is an **educational resource** for research compounds. We do **not endorse** human consumption of any compound. BodyHackGuide and **BHG Labs share common ownership**; we rank every vendor on the same public methodology, and we earn a commission on purchases through our links. By entering, you confirm you are **21 years of age or older** and agree to our [Terms](/terms) & [Privacy Policy](/privacy). I'm 21+ — Enter SiteLeave site [![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp)BodyHackGuide ](/) [Compare](/compare)[Wiki](/wiki)[Vendors](/vendors)[Deals](/deals)[Stacks](/stack-builder)[Nootropics](/nootropics)[Tools](/tools) Learn Community Search ⌘K [Sign In](/auth?returnTo=%2Fcompound%2Feloralintide) 100K+ researchers trust BodyHackGuide — Join [r/BodyHackGuide](https://reddit.com/r/bodyhackguide) 1. [Home](/) 2. [Compounds](/compare) 3. Eloralintide (LY3841136) ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Best price right now $18.00/mg · $179.99 for 10mg at Disguised Alpha [Buy at Disguised Alpha](https://www.bodyhackguide.co/go/disguised-alpha?utm_source=compound-sticky-bar&utm_campaign=0255864e-8f76-4f53-ba2d-61064bb8c77d&utm_medium=best-price-cta) [Where to buy Eloralintide (LY3841136)](/buy/eloralintide) [Eloralintide (LY3841136) coupon codes](/coupons/eloralintide) [Eloralintide (LY3841136) protocol](/protocol/eloralintide) [Alternatives to Eloralintide (LY3841136)](/alternatives-to/eloralintide) [Eloralintide (LY3841136) side effects](/side-effects/eloralintide) 1. [Home](/) 3. [Compounds](/compare) 5. Eloralintide (LY3841136) ![Eloralintide (LY3841136) molecular structure](/assets/peptide-structure-placeholder-DUmZBF_j.png) # Eloralintide (LY3841136) Weight Loss Phase 3 Download PDF Also known as: LY3841136, LY-3841136, AT53786, Eloralintida Eloralintide is an amylin analog developed by Eli Lilly and Company for weight management, given as a once-weekly subcutaneous injection. It is a 37 amino acid peptide containing three non-coded residues and a C20 fatty diacid that binds albumin, which is what stretches its action out to a week (PMID: 41109426). Half-Life: Terminal geometric mean half-life 310 to 366 hours, that is 12.9 to 15.3 days, across the doses tested in the phase 1 single-ascending-dose study in humans (PMID: 41109426) Route: Subcutaneous injection MW: 4526 g/mol CAS: 2883634-40-8 Last reviewed: Sep 7, 2026 [ Weight Loss Category ](/wiki#cat-weight-loss) Phase 3 Research Stage OverviewChemical InfoDosing & ProtocolsInteractionsResearchCompare Prices1 Related ## Overview ### Best Price Available ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Disguised Alpha $179.99 1 vial (10 mg) · vial [Buy Now](https://disguisedalpha.com/product/eloralintide/?coupon=reddit) Compare 1 vendor ### At A Glance Mechanism Eloralintide is a selective agonist at the amylin 1 receptor, a complex formed by the calcitonin receptor with receptor activity-modifying protein 1. Activating that receptor in the area postrema and related hindbrain circuits promotes satiation, slows gastric emptying and suppre… Half-Life Terminal geometric mean half-life 310 to 366 hours, that is 12.9 to 15.3 days, across the doses tested in the phase 1 single-ascending-dose study in humans (PMID: 41109426) Routes Subcutaneous injection Potential Benefits Mean body weight change from baseline of about 9 percent to 20 percent across dose groups at 48 weeks against 0.4 percent on placebo in a 263-patient phase 2 trial in adults with obesity or overweight (PMID: 41207310) Weight reduction of 2.6 percent to 11.3 percent across dose groups at 12 weeks in 100 adults with obesity or overweight in a phase 1 multiple-ascending-dose study (PMID: 41559929) Week 4 weight reduction of 2.5 percent and 4.4 percent after single doses in healthy participants against a 0.6 percent gain on placebo (PMID: 41109426) Dose-dependent reduction in food intake and body weight, mainly through fat mass loss, in diet-induced obese rats (PMID: 41109426) Significantly less conditioned taste avoidance than cagrilintide in lean rats, a marker of reduced aversive signaling (PMID: 41109426) ### Overview Eloralintide is an amylin analog developed by Eli Lilly and Company for weight management, given as a once-weekly subcutaneous injection. It is a 37 amino acid peptide containing three non-coded residues and a C20 fatty diacid that binds albumin, which is what stretches its action out to a week (PMID: 41109426). It is investigational everywhere. No regulator has approved it, and it is in phase 3 trials as of 2026. Amylin is a hormone released from pancreatic beta cells alongside insulin. It slows gastric emptying, suppresses glucagon after meals and signals meal termination through the brainstem. Pramlintide, the first approved amylin analog, proved the concept but was limited by frequent dosing and modest effect. The newer analogs split into two groups: dual amylin and calcitonin receptor agonists such as cagrilintide, and selective amylin receptor agonists. Eloralintide belongs to the second group. In cells expressing human receptors it activated the amylin 1 receptor about 12-fold more potently than the calcitonin receptor and about 11-fold more potently than the amylin 3 receptor (PMID: 41109426). That selectivity is the design idea, because calcitonin receptor engagement is thought to contribute to nausea. Preclinical results back this up. In lean rats, eloralintide produced significantly less conditioned taste avoidance than cagrilintide, a marker of aversive signaling. In diet-induced obese rats it reduced food intake and lowered body weight in a dose-dependent way, mostly through loss of fat mass, and pharmacokinetics in rats and monkeys supported weekly dosing (PMID: 41109426). The human data are what make this compound notable. A phase 1 single-ascending-dose study in 48 healthy participants reported mostly mild adverse events and week 4 weight reduction of 2.5 percent and 4.4 percent in the two highest single-dose groups against a 0.6 percent gain on placebo (NCT05295940, PMID: 41109426). A 12-week multiple-ascending-dose study in 100 participants with obesity or overweight, run without dose escalation, reported weight reduction across dose groups ranging from 2.6 percent to 11.3 percent, with decreased appetite in 19 percent, headache in 12 percent and fatigue in 11 percent, and infrequent gastrointestinal events: diarrhea in 10 percent, nausea in 8 percent and vomiting in 4 percent (PMID: 41559929). A 48-week phase 2 trial randomized 263 adults across six dose or dose-escalation arms and placebo and reported mean weight change from baseline of about 9 percent to 20 percent against 0.4 percent on placebo, with nausea and fatigue the most common adverse events (NCT06230523, PMID: 41207310). A network meta-analysis of six trials in 4642 adults ranked high-dose eloralintide second only to amycretin for percent body weight reduction, ahead of semaglutide, while noting that gastrointestinal adverse events rose with high doses of amylin-based therapies and that the evidence is still sparse and low certainty (PMID: 42175595). Anything sold outside a trial is not the studied product and has no verified identity or purity. ### Potential Research Fields Obesity pharmacotherapy Amylin receptor pharmacology Metabolic disease Appetite regulation ## Chemical Information IUPAC Name Not yet available CAS Number 2883634-40-8 Molecular Formula C201H319N49O65S2 Molecular Mass 4526 g/mol ![Eloralintide (LY3841136) molecular structure](https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/175663130/PNG) [View on PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/175663130) ## Dosing & Protocols ### Unlock Dosing Protocols Free account gets you: - View beginner, intermediate & advanced protocols - See weight-based dosing calculations - Access cycle length & frequency data [Create free account](/auth)[Sign in](/auth) 2,800+ researchers already in ## Research ### Unlock Research Data Free account gets you: - Browse PubMed study summaries - See clinical trial phases & results - Access mechanism of action details [Create free account](/auth)[Sign in](/auth) 2,800+ researchers already in ## Interactions ### Contraindications No labeled contraindications exist, since the drug is not approved. Trial-based and mechanism-based: the phase 2 program enrolled adults with obesity or overweight and excluded people outside those criteria, so nothing is known about use in people at a healthy weight. Because amylin receptor agonists slow gastric emptying, pre-existing gastroparesis or severe gastrointestinal disease is a mechanism-based reason for caution, and the ongoing program includes dedicated hepatic and renal impairment pharmacokinetic studies precisely because those populations have not been characterized (NCT07401862, NCT07426380). Pregnancy and breastfeeding have not been studied. Research Disclaimer This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds. Best Price $179.99 Best $/mg $17.9990 Vendors 1 Listings 1 vial [Sign in for alerts ](/auth) Form Allvial Sort Price $/mg Vendor Vendor Product Form Qty Price $/mg Coupon ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) [Disguised Alpha](/vendor/disguised-alpha) [50 ](/vendor-trust-scorecard) 🇺🇸 US 🇪🇺 EU 🇬🇧 UK Eloralintide 10 mg vial 1 vial (10 mg) ● In Stock $179.99 BEST $17.999 — [Buy](https://disguisedalpha.com/product/eloralintide/?coupon=reddit) Get Eloralintide (LY3841136) Price Drop Alerts Set a target price and we'll notify you when any vendor drops below it. Current lowest: $179.99 [Sign in to set alerts](/auth) ### Sign in to leave a review Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with Eloralintide (LY3841136). [Sign in](/auth) Current low $179.99 as of Sep 7, 2026 7-day low $179.99 30-day low $179.99 30-day change — baseline building Tracking since Sep 7, 2026 · 1 data point ### Vendors Selling Eloralintide (LY3841136) [ ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) #### Disguised Alpha 1 listing · from $179.99 ](/vendor/disguised-alpha) How we score these vendors Every supplier above is graded 0–100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. [View Scorecard](/vendors/scorecard) ### Related Compounds [View All](/wiki) [ ### 5-Amino-1MQ Weight Loss Preclinical 5-Amino-1MQ (5-amino-1-methylquinolinium iodide) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that transfers a methyl group from S-adenosyl-L-methionine (SAM) to nicotinamide to form 1-methylnicotinamide (1-MNA) and S-adenosyl-L-homocysteine (SAH). t½ ~6–12 hours (oral) 50 mg - 150 mg daily (oral or injection) Preclinical View Profile ](/compound/5-amino-1mq)[ ### BAM15 Weight Loss Preclinical BAM15 is a small-molecule mitochondrial protonophore uncoupler that was first described in 2014 as a tool compound for dissipating proton motive force selectively across the inner mitochondrial membrane without collapsing the plasma membrane electrochemical gradient (\[Kenwood et al., 2014\]). Research compound — no established human doses. Animal studies use 10-100 mg/kg 58 studies View Profile ](/compound/bam15)[ ### Exenatide Weight Loss FDA-approved Exenatide (Byetta, Bydureon) is a synthetic exendin-4 GLP-1 receptor agonist, FDA-approved for type 2 diabetes, that lowers blood glucose and curbs appetite. t½ Immediate-release (Byetta): terminal half-life about 2.4 hours, cleared mainly by the kidneys. Extended-release (Bydureon): the same peptide is released slowly from biodegradable microspheres over roughly 10 weeks, reaching steady-state plasma levels by about 6 to 7 weeks. 5 to 10 mcg twice daily (Byetta, immediate-release) or 2000 mcg (2 mg) once weekly (Bydureon, extended-release) Preclinical View Profile ](/compound/exenatide)[ ### L-Carnitine Weight Loss Preclinical L-Carnitine is a naturally occurring quaternary ammonium compound synthesized in the body from the amino acids lysine and methionine, with essential cofactor roles in fatty acid metabolism, energy production, and cellular health. 500 mg - 2000 mg daily (oral or injection) 23241 studies View Profile ](/compound/l-carnitine)[ ### Lipo-C Weight Loss No clinical trials of the blend (marketed compounded injection) Lipo-C (also sold as a MIC or "lipotropic" injection) is a compounded blend of methionine, inositol, and choline, usually with vitamin B12 and sometimes L-carnitine, marketed by medspas and weight-loss clinics to support fat metabolism and energy. t½ Not applicable to the blend; the water-soluble components (choline, inositol, B-vitamins, carnitine) are cleared over hours to a few days, and excess is largely excreted. 1 mL of a compounded MIC blend intramuscularly, 1 to 2x per week. No standardized dose exists; concentrations vary by compounding pharmacy. Preclinical View Profile ](/compound/lipo-c)[ ### Mazdutide Weight Loss Approved (China, NMPA 2025); investigational in US/EU Mazdutide (also known as IBI362, Lilly compound LY3305677) is a dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist originally discovered by Eli Lilly and exclusively licensed to Innovent Biologics in 2019 for development and commercialization in Mainland China, Hong Kong, Macau, and Taiwan. Research doses — clinical trial protocols vary 39 studies View Profile ](/compound/mazdutide) [ View Full Dosage Guide → Protocols, calculator & safety for Eloralintide (LY3841136) ](/guides/dosage/eloralintide) ### Best Price ![Disguised Alpha logo](https://disguisedalpha.com/wp-content/themes/assets/logos/disguised-logo-2x.png) Disguised Alpha $179.99 [Buy Now](https://disguisedalpha.com/product/eloralintide/?coupon=reddit) 1 vendors · 1 listings ### Research Score 30 0 PubMed studies ### Quality Indicators Data Completeness 63% Description Mechanism of Action Chemical Data Dosing Protocols Safety Profile PubMed Studies Interactions Vendor Listings ### Quick Facts Half-Life Terminal geometric mean half-life 310 to 366 hours, that is 12.9 to 15.3 days, across the doses tested in the phase 1 single-ascending-dose study in humans (PMID: 41109426) Molecular Weight 4526 g/mol Administration Subcutaneous injection CAS Number 2883634-40-8 Trial Phase Phase 3 0 [Full Dosage Guide](/guides/dosage/eloralintide)[Calculate Your Dose](/tools/reconstitution) Research Disclaimer This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use. ## Frequently Asked Questions What is Eloralintide (LY3841136) used for in research? Eloralintide is an amylin analog developed by Eli Lilly and Company for weight management, given as a once-weekly subcutaneous injection. It is a 37 amino acid peptide containing three non-coded residues and a C20 fatty diacid that binds albumin, which is what stretches its action out to a week (PMID: 41109426). It is investigational everywhere. No regulator has approved it, and it is in phase 3 trials as of 2026. Amylin is a hormone released from pancreatic beta cells alongside insulin. It slows gastric emptying, suppresses glucagon after meals and signals meal termination through the brainstem. Pramlintide, the first approved amylin analog, proved the concept but was limited by frequent dosing and modest effect. The newer analogs split into two groups: dual amylin and calcitonin receptor agonists such as cagrilintide, and selective amylin receptor agonists. Eloralintide belongs to the second group. In cells expressing human receptors it activated the amylin 1 receptor about 12-fold more potently than the calcitonin receptor and about 11-fold more potently than the amylin 3 receptor (PMID: 41109426). That selectivity is the design idea, because calcitonin receptor engagement is thought to contribute to nausea. Preclinical results back this up. In lean rats, eloralintide produced significantly less conditioned taste avoidance than cagrilintide, a marker of aversive signaling. In diet-induced obese rats it reduced food intake and lowered body weight in a dose-dependent way, mostly through loss of fat mass, and pharmacokinetics in rats and monkeys supported weekly dosing (PMID: 41109426). The human data are what make this compound notable. A phase 1 single-ascending-dose study in 48 healthy participants reported mostly mild adverse events and week 4 weight reduction of 2.5 percent and 4.4 percent in the two highest single-dose groups against a 0.6 percent gain on placebo (NCT05295940, PMID: 41109426). A 12-week multiple-ascending-dose study in 100 participants with obesity or overweight, run without dose escalation, reported weight reduction across dose groups ranging from 2.6 percent to 11.3 percent, with decreased appetite in 19 percent, headache in 12 percent and fatigue in 11 percent, and infrequent gastrointestinal events: diarrhea in 10 percent, nausea in 8 percent and vomiting in 4 percent (PMID: 41559929). A 48-week phase 2 trial randomized 263 adults across six dose or dose-escalation arms and placebo and reported mean weight change from baseline of about 9 percent to 20 percent against 0.4 percent on placebo, with nausea and fatigue the most common adverse events (NCT06230523, PMID: 41207310). A network meta-analysis of six trials in 4642 adults ranked high-dose eloralintide second only to amycretin for percent body weight reduction, ahead of semaglutide, while noting that gastrointestinal adverse events rose with high doses of amylin-based therapies and that the evidence is still sparse and low certainty (PMID: 42175595). Anything sold outside a trial is not the studied product and has no verified identity or purity. What forms does Eloralintide (LY3841136) come in? Eloralintide (LY3841136) is available in vial form. How much does Eloralintide (LY3841136) cost? Prices start at $179.99 across 1 verified vendor. How do I compare Eloralintide (LY3841136) vendors? Compare prices, payment methods, shipping, and COA scores across 1 vendor. ## Research Tools [ ### Peptide Calculator Reconstitution & syringe units ](/tools/reconstitution)[ ### Reconstitution Guide How to mix, step by step ](/guides/how-to-reconstitute-peptides)[ ### Nasal Spray Calc mL per actuation ](/tools/intranasal)[ ### Half-Life Visualizer Decay curves ](/tools/halflife) ## Related Compounds [View All](/wiki) [ ### 5-Amino-1MQ Weight Loss Preclinical 5-Amino-1MQ (5-amino-1-methylquinolinium iodide) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that transfers a methyl group from S-adenosyl-L-methionine (SAM) to nicotinamide to form 1-methylnicotinamide (1-MNA) and S-adenosyl-L-homocysteine (SAH). t½ ~6–12 hours (oral) 50 mg - 150 mg daily (oral or injection) Preclinical View Profile ](/compound/5-amino-1mq)[ ### BAM15 Weight Loss Preclinical BAM15 is a small-molecule mitochondrial protonophore uncoupler that was first described in 2014 as a tool compound for dissipating proton motive force selectively across the inner mitochondrial membrane without collapsing the plasma membrane electrochemical gradient (\[Kenwood et al., 2014\]). Research compound — no established human doses. Animal studies use 10-100 mg/kg 58 studies View Profile ](/compound/bam15)[ ### Exenatide Weight Loss FDA-approved Exenatide (Byetta, Bydureon) is a synthetic exendin-4 GLP-1 receptor agonist, FDA-approved for type 2 diabetes, that lowers blood glucose and curbs appetite. t½ Immediate-release (Byetta): terminal half-life about 2.4 hours, cleared mainly by the kidneys. Extended-release (Bydureon): the same peptide is released slowly from biodegradable microspheres over roughly 10 weeks, reaching steady-state plasma levels by about 6 to 7 weeks. 5 to 10 mcg twice daily (Byetta, immediate-release) or 2000 mcg (2 mg) once weekly (Bydureon, extended-release) Preclinical View Profile ](/compound/exenatide)[ ### L-Carnitine Weight Loss Preclinical L-Carnitine is a naturally occurring quaternary ammonium compound synthesized in the body from the amino acids lysine and methionine, with essential cofactor roles in fatty acid metabolism, energy production, and cellular health. 500 mg - 2000 mg daily (oral or injection) 23241 studies View Profile ](/compound/l-carnitine)[ ### Lipo-C Weight Loss No clinical trials of the blend (marketed compounded injection) Lipo-C (also sold as a MIC or "lipotropic" injection) is a compounded blend of methionine, inositol, and choline, usually with vitamin B12 and sometimes L-carnitine, marketed by medspas and weight-loss clinics to support fat metabolism and energy. t½ Not applicable to the blend; the water-soluble components (choline, inositol, B-vitamins, carnitine) are cleared over hours to a few days, and excess is largely excreted. 1 mL of a compounded MIC blend intramuscularly, 1 to 2x per week. No standardized dose exists; concentrations vary by compounding pharmacy. Preclinical View Profile ](/compound/lipo-c)[ ### Mazdutide Weight Loss Approved (China, NMPA 2025); investigational in US/EU Mazdutide (also known as IBI362, Lilly compound LY3305677) is a dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist originally discovered by Eli Lilly and exclusively licensed to Innovent Biologics in 2019 for development and commercialization in Mainland China, Hong Kong, Macau, and Taiwan. Research doses — clinical trial protocols vary 39 studies View Profile ](/compound/mazdutide) Free 2026 Peptide Cheat Sheet — 50 pages, PDF Reconstitution math, concentration charts, half-lives, and vendor trust tiers. The reference we wish we had on day one. [Download Free](/guides/peptide-cheat-sheet-download?utm_source=compound-eloralintide) ### Need bloodwork before starting? Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount. [Order Bloodwork](https://anabolicinsights.ai/?ref=nwm2zjb) ![BodyHackGuide](/assets/bodyhackguide-logo-DOzZNUyh.webp) ### BodyHackGuide Your biohacking research hub — compound pricing, brain health protocols, dosing tools, and vendor reviews. [support@bodyhackguide.co](mailto:support@bodyhackguide.co) [](https://discord.gg/Mhq5UdRYBA)[](https://reddit.com/r/BodyHackGuide)[](https://x.com/bodyhackguide) Explore #### Explore - [Compare prices](/compare) - [Research suppliers](/vendors) - [Deals](/deals) - [Coupons](/coupons) - [Nootropics](/nootropics) - [Brain health](/brain-health) - [Blog](/blog) - [Guides](/guides) Tools #### Tools - [Reconstitution](/tools/reconstitution) - [Dosage calculator](/tools/dosage) - [Half-life visualizer](/tools/halflife) - [COA lookup](/tools/coa) - [Cost calculator](/tools/cost-calculator) - [Stack builder](/stack-builder) - [All tools →](/tools) Trust & vendors #### Trust & vendors - [Vendor directory](/vendors) - [Trust scorecard](/vendors/scorecard) - [Get BHG verified](/vendors/get-vetted) - [Scoring methodology](/vendors/methodology) - [Peptide cheatsheet](/guides/peptide-cheat-sheet-download) Company #### Company - [About](/about) - [Affiliate disclosure](/affiliate-disclosure) - [Editorial standards](/editorial-standards) - [Creators](/creators) - [Coaches](/coaches) - [Privacy](/privacy) - [Terms](/terms) - [Full site directory →](/site-directory) **Ownership & Affiliate Disclosure:** BodyHackGuide and BHG Labs share common ownership. We rank every vendor on the same public, reproducible [methodology](/vendors/methodology), and we earn a commission from purchases made through our links at no extra cost to you. Full details in our [affiliate disclosure](/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell, distribute, or promote any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. · [Terms](/terms) · [Privacy](/privacy) hi 👋